The Asthma Treatment Blind Spot No One Talks About (and How GLP-1s Can Help) w/ Dr. Atoosa Kourosh

Asthma is often treated like a lung problem. The tighter the chest, the more inflamed the airway, the worse the flare-up, the answer has usually been to reach for medications designed to calm the lungs directly.

But what if, for some patients, the real driver is not only in the lungs at all?

For years, clinicians have recognized that patients with both obesity and asthma often experience a more difficult form of the disease. Their symptoms are more severe. Their flare-ups are more frequent. Their quality of life is lower. And frustratingly, many do not respond as well to the standard asthma therapies we rely on, including inhaled steroids.

That is because obesity-related asthma is not simply “asthma plus extra weight.” It appears to be a distinct phenotype shaped by metabolic dysfunction, systemic inflammation, insulin resistance, altered immune signaling, and the mechanical effects of excess weight on lung function. In other words, for some patients with obesity-associated asthma, systemic metabolic and inflammatory processes may contribute substantially to disease in the airways.

That shift in thinking is why the growing research around GLP-1 receptor agonists is so compelling. These medications, originally developed for type 2 diabetes and now widely known for their role in weight management, may be doing far more than changing blood sugar or body weight. Emerging preclinical and observational research suggests GLP-1 receptor agonists may influence inflammatory and airway pathways and may be associated with fewer asthma exacerbations. Researchers are also investigating whether some effects may occur independently of weight loss.

To explore what this could mean for the future of asthma care, Dr. Atoosa Kourosh, a board-certified allergist, immunologist, and pediatrician with more than two decades of clinical experience, returns to the show. 

She is the founder of Holistic Allergy and Immunology and chair of the Integrative Medicine Committee at the American College of Allergy, Asthma, and Immunology, where she brings together conventional medicine, lifestyle medicine, metabolic health, and integrative care.

Our traditional therapies, like inhaled steroids, are really designed for T2-high disease. So we’re essentially using the wrong tools that miss the mark for a different biology, which is why outcomes are suboptimal when we treat obese asthmatics. -Dr. Atoosa Kourosh

 

Together, we explore:

• Why obesity-related asthma is not just “regular asthma in a heavier body,” but a distinct phenotype with different biology, different inflammation, and often a different response to treatment
• How metabolic dysfunction, insulin resistance, adipokines, immune reprogramming, and systemic inflammation can all shape what happens in the lungs
• Why some patients with obesity-associated asthma may respond less well to standard therapies, particularly when metabolic and non–type 2 inflammatory pathways contribute to their disease
• What emerging research suggests about GLP-1 receptor agonists and their potential effects on airway inflammation, airway smooth-muscle signaling, and asthma exacerbation risk
• Why researchers are investigating whether some respiratory benefits of GLP-1 receptor agonists could occur partly independently of weight loss
• What real-world data can and cannot tell us about GLP-1 medications, asthma attacks, and patients with both asthma and type 2 diabetes
• Why randomized controlled trials are needed to determine whether GLP-1 receptor agonists have a therapeutic role in asthma beyond their established metabolic and weight-management indications
• What clinicians and families should consider when GLP-1 medications are being considered for an adolescent who also has asthma, including growth, muscle loss, bone health, mental health, activity levels, and the need for careful testing and monitoring
• Why these medications should be viewed as one tool in a broader lifestyle and integrative medicine toolkit, not a quick fix or a substitute for nutrition, movement, sleep, stress regulation, and anti-inflammatory living
• How this research could change the way we classify asthma in the future, moving from a lung-only model to a more metabolic, systems-based model of chronic inflammatory disease

If you are a clinician treating difficult-to-control asthma, a patient living with asthma and metabolic dysfunction, or someone trying to understand why chronic disease rarely fits into one neat category, this conversation will challenge you to look beyond the lungs and consider the whole body story.

Learn More About My Virtual Medical Practice

Exciting news: my virtual medical practice is now open!

I am currently seeing patients in Arizona, Connecticut, and Massachusetts, with additional states coming soon. If you live in one of these three states, you can schedule a consultation. If you live elsewhere, join the waitlist to be notified as availability expands. 

Precision care. Personalized guidance. Wherever you are.